Renal denervation in the treatment of drug-resistant hypertension: current knowledge and future perspectives

References

• Calhoun DA, Jones D, Textor S et al.; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117(25), e510–e526 (2008).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455), 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 57(6), 1076–1080 (2011).
   PubMed Web of Science ®Google Scholar
• Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br. Med. J. 2(6035), 554–556 (1976).
   PubMed Web of Science ®Google Scholar
• Pedrosa RP, Drager LF, Gonzaga CC et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 58(5), 811–817 (2011).
   PubMed Web of Science ®Google Scholar
• Baglivo HP, Sánchez RA. Secondary arterial hypertension: improvements in diagnosis and management in the last 10 years. Am. J. Ther. 18(5), 403–415 (2011).
   Google Scholar
• Esler M. The sympathetic system and hypertension. Am. J. Hypertens. 13(6 Pt 2), 99S–105S (2000).
   Google Scholar
• Müller J, Barajas L. Electron microscopic and histochemical evidence for a tubular innervation in the renal cortex of the monkey. J. Ultrastruct. Res. 41(5), 533–549 (1972).
   PubMedGoogle Scholar
• DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289(3), R633–R641 (2005).
   PubMed Web of Science ®Google Scholar
• DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298(2), R245–R253 (2010).
   PubMed Web of Science ®Google Scholar
• Osborn JW, Fink GD, Kuroki MT. Neural mechanisms of angiotensin II-salt hypertension: implications for therapies targeting neural control of the splanchnic circulation. Curr. Hypertens. Rep. 13(3), 221–228 (2011).
   Google Scholar
• Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 54(6), 1195–1201 (2009).
   PubMed Web of Science ®Google Scholar
• Zanchetti AS. Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 56(5), 691–698 (1977).
   PubMed Web of Science ®Google Scholar
• Kon V. Neural control of renal circulation. Miner. Electrolyte Metab. 15(1–2), 33–43 (1989).
   Google Scholar
• Kumagai H, Oshima N, Matsuura T et al. Importance of rostral ventrolateral medulla neurons in determining efferent sympathetic nerve activity and blood pressure. Hypertens. Res. 35(2), 132–141 (2012).
   PubMed Web of Science ®Google Scholar
• Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 106(15), 1974–1979 (2002).
   PubMed Web of Science ®Google Scholar
• Freyberg RH, Peet MM. The effect on the kidney of bilateral splanchnicectomy in patients with hypertension. J. Clin. Invest. 16(1), 49–65 (1937).
   PubMedGoogle Scholar
• Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1266 cases. J. Am. Med. Assoc. 152(16), 1501–1504 (1953).
   PubMed Web of Science ®Google Scholar
• Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1(6757), 403–408 (1953).
   PubMed Web of Science ®Google Scholar
• Evelyn KA, Singh MM, Chapman WP, Perera GA, Thaler H. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am. J. Med. 28, 188–221 (1960).
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671), 1275–1281 (2009).
   PubMed Web of Science ®Google Scholar
• Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog. Cardiovasc. Dis. 48(6), 387–396 (2006).
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376, 1903–1909 (2010).
   PubMed Web of Science ®Google Scholar
• Kidney disease outcomes quality initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 45, S1–290 (2004).
   Google Scholar
• Mancia G, Lanfranchi A, Turri C, Grassi G. Can good surrogate end-points predict the prognosis of hypertensive patients? J. Hypertens. Suppl. 16(5), S3–S7 (1998).
   Google Scholar
• Prisant LM. Ambulatory blood pressure monitoring: test reproducibility and its implications. Blood Press. Monit. 3(4), 221–225 (1998).
   PubMedGoogle Scholar
• Prochnau D, Lucas N, Kuehnert H, Figulla HR, Surber R. Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter. EuroIntervention 7(9), 1077–1080 (2012).
   Google Scholar
• Prochnau D, Figulla HR, Surber R. Efficacy of renal denervation with a standard EP catheter in the 24-h ambulatory blood pressure monitoring-long-term follow-up. Int. J. Cardiol. 157(3), 447–448 (2012).
   Google Scholar
• Ahmed H, Neuzil P, Skoda J et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc. Interv. 5(7), 758–765 (2012).
   PubMed Web of Science ®Google Scholar
• Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 58(4), 559–565 (2011).
   PubMed Web of Science ®Google Scholar
• Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J. Hypertens. 22(3), 435–445 (2004).
   PubMed Web of Science ®Google Scholar
• Ishikawa J, Carroll DJ, Kuruvilla S, Schwartz JE, Pickering TG. Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis. Hypertension 52(5), 856–864 (2008).
   PubMed Web of Science ®Google Scholar
• Bunte MC. Renal sympathetic denervation for refractory hypertension. Lancet 377(9771), 1074; author reply 1074–1074; author reply 1075 (2011).
   Google Scholar
• Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Sympathetic neural mechanisms in white-coat hypertension. J. Am. Coll. Cardiol. 40(1), 126–132 (2002).
   PubMed Web of Science ®Google Scholar
• Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J. Hypertens. 25(11), 2193–2198 (2007).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57, 911–917 (2011).
   PubMed Web of Science ®Google Scholar
• Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 60(3), 596–606 (2012).
   PubMed Web of Science ®Google Scholar
• Voskuil M, Verloop WL, Blankestijn PJ, Agostoni P, Stella PR, Doevendans PA. Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience. Neth. Heart J. 19(7–8), 319–323 (2011).
   PubMed Web of Science ®Google Scholar
• Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention 8(1), 57–61 (2012).
   PubMed Web of Science ®Google Scholar
• Deisenhofer I, Zrenner B, Yin YH et al. Cryoablation versus radiofrequency energy for the ablation of atrioventricular nodal reentrant tachycardia (the CYRANO study): results from a large multicenter prospective randomized trial. Circulation 122(22), 2239–2245 (2010).
   Google Scholar
• Malmborg H, Lönnerholm S, Lundqvist CB. A prospective randomised comparison of large-tip cryoablation and 8-mm-tip radiofrequency catheter ablation of atrial flutter. J. Interv. Card. Electrophysiol. 24(2), 127–131 (2009).
   Google Scholar
• Prochnau D, Figulla HR, Romeike BF et al. Percutaneous catheter-based cryoablation of the renal artery is effective for sympathetic denervation in a sheep model. Int. J. Cardiol. 152(2), 268–270 (2011).
   Google Scholar
• Kang CS, Chen CC, Lin CC, Chang NC, Lee TM. Effect of ATP-sensitive potassium channel agonists on sympathetic hyperinnervation in postinfarcted rat hearts. Am. J. Physiol. Heart Circ. Physiol. 296(6), H1949–H1959 (2009).
   Google Scholar
• Prochnau D, Figulla HR, Surber R. Cryoenergy is effective in the treatment of resistant hypertension in non-responders to radiofrequency renal denervation. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.09.224 (2012) (Epub ahead of print).
   Google Scholar
• Vollenweider P, Tappy L, Randin D et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J. Clin. Invest. 92(1), 147–154 (1993).
   PubMed Web of Science ®Google Scholar
• Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of Type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108(25), 3097–3101 (2003).
   PubMed Web of Science ®Google Scholar
• Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. 334(6), 374–381 (1996).
   PubMed Web of Science ®Google Scholar
• Grassi G, Mancia G. Neurogenic hypertension: is the enigma of its origin near the solution? Hypertension 43(2), 154–155 (2004).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311(13), 819–823 (1984).
   PubMed Web of Science ®Google Scholar
• Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur. Heart. J. 22, 1136–1143 (2001).
   PubMed Web of Science ®Google Scholar
• Petersson M, Friberg P, Lambert G, Rundqvist B. Decreased renal sympathetic activity in response to cardiac unloading with nitroglycerin in patients with heart failure. Eur. J. Heart Fail. 7(6), 1003–1010 (2005).
   Google Scholar
• Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18), 1940–1946 (2011).
   PubMed Web of Science ®Google Scholar
• Brandt MC, Mahfoud F, Reda S et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J. Am. Coll. Cardiol. 59(10), 901–909 (2012).
   PubMed Web of Science ®Google Scholar
• Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J. Am. Soc. Nephrol. 23(7), 1250–1257 (2012).
   PubMed Web of Science ®Google Scholar
• Prochnau D, Lauten A, Busch M, Kuehnert H, Figulla HR, Surber R. Catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system for drug resistant hypertension in a patient with end-stage renal disease. Int. J. Cardiol. 154(2), e29–e30 (2012).
   Google Scholar
• Pokushalov E, Romanov A, Corbucci G et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J. Am. Coll. Cardiol. 60(13), 1163–1170 (2012).
   PubMed Web of Science ®Google Scholar
• Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur. Heart J. 33(9), 1058–1066 (2012).
   PubMed Web of Science ®Google Scholar
• Geisler BP, Egan BM, Cohen JT et al. Cost–effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J. Am. Coll. Cardiol. 60(14), 1271–1277 (2012).
   PubMed Web of Science ®Google Scholar
• Dorenkamp M, Bonaventura K, Leber AW et al. Potential lifetime cost–effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur. Heart J. (2012).
   Google Scholar
• Kandzari DE, Bhatt DL, Sobotka PA et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin. Cardiol. 35(9), 528–535 (2012).
   PubMed Web of Science ®Google Scholar